Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 15/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24350163 | 0.78 | NISCH (0.51) | MAOAMAOBNISCHKDM4ECYP1A2 | |
| SCHEMBL548286 | 0.78 | NISCH (0.55) | NISCHKDM4ECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL10199676 | 0.74 | NISCH (0.57) | MAOAMAOBNISCHKDM4ECYP1A2 | |
| SCHEMBL14286968 | 0.68 | NISCH (0.56) | NISCHKDM4ECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL30382864 | 0.68 | NISCH (0.56) | NISCHKDM4ECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL2625467 | 0.67 | AURKA (0.53) | KDM4E | |
| SCHEMBL27612098 | 0.67 | NISCH (0.59) | NISCHKDM4ECYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL6845023 | 0.66 | KDM4E (0.55) | KDM4ECYP1A2ALDH1A1ALOX15LMNA | |
| SCHEMBL28903852 | 0.66 | TAAR1 (0.57) | NISCH | |
| SCHEMBL18719694 | 0.66 | NISCH (1.00) | MAOAMAOBNISCHLMNAHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | MAOA 4572/4885MAOB 4438/4885NISCH 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.